Brind.
  1. KalVista Pharmaceuticals received prior regulatory approvals in the UK and the US, and the EMA adopted a positive opinion for its drug sebetralstat, with the EC expected to make a final decision.

FDA approved KalVista's novel treatment EKTERLY®.

4 reports, 0 independent Updated Jul 9
Gone quiet
Reports
4
Developments
3
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

FDA approved KalVista's novel treatment EKTERLY®.

Who's involved

What this event is mainly about
FDA

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA approved KalVista's Ekterly treatment, leading to a royalty agreement with DRI Healthcare.Sub-event
  2. FDA grants approval for KalVista's new treatment EKTERLY®.
  3. BofA raised price target for KalVista following Ekterly's approval.

Keep exploring

Part of

KalVista Pharmaceuticals received prior regulatory approvals in the UK and the US, and the EMA adopted a positive opinion for its drug sebetralstat, with the EC expected to make a final decision. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet